If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
336
results.
Updated on
20/08/2026 [07:44:00]
Results 75 to 100 of 336
Absstract of: WO2026161305A2
Disclosed herein are conformationally stable variants of a single-chain circular permuted caspase, crystalline forms thereof, and methods of their preparation and use.
Absstract of: WO2026161463A1
Disclosed is a method of diagnosing a subject with ALS, the method including measuring the amount of OxPL on apolipoprotein E, E2, E3 and/or E4.
Absstract of: US20260216274A1
A method of treating a patient with moderate-to-severee traumatic brain injury (TBI) undergoing emergency craniotomy includes administering, in addition to orthodox therapy (OT), intravenous Xingnaojing (XNJ) for seven consecutive days in an intensive care setting, wherein acute postoperative neurological recovery is improved as measured by Glasgow Coma Scale (GCS) during postoperative Days 1, 3, 5, and 7, wherein long-term functional outcome is improved as measured by Glasgow Outcome Scale (GOS) and Karnofsky Performance Status (KPS) at 30 and 90 days, and wherein secondary-injury biomarkers are modulated by reducing serum S100B and preserving or restoring serum superoxide dismutase (SOD) activity relative to OT alone.
Absstract of: WO2026160244A1
A visualization agent for visualizing the aggregation state of a protein according to an embodiment contains a chemical probe molecule that binds to the protein in an aggregated state to form a complex. The chemical probe molecule is an aminocoumarin analog having a leaving group that leaves due to the formation of the complex. A method for visualizing the aggregation state of a protein according to an embodiment comprises: a contact step for bringing a visualization agent into contact with an aggregated protein; and a detection step for detecting the fluorescence of a complex of the aggregated protein and the visualization agent.
Absstract of: WO2025024816A1
The invention is directed to (6aS)-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzode,gquinoline-10,11-diol for the treatment of diseases mediated by protein expressions and gene regulations, as well as the use of personalized medicine approach.
Absstract of: WO2026160417A1
The present invention addresses the problem of providing: a device, a method, and a program for easily, quickly, and accurately classifying and/or identifying a cell type of a living or fixed cell, particularly a cell of the nervous system, head, or the like; and a neural network training method for the device, the method, or the program. In the present invention, a neural network is trained by using two-dimensional and black-and-white training image data based on captured images of stained cell nuclei and training data including information related to cell types corresponding to the cells, thereby making it possible to inexpensively, quickly, and easily classify/identify a cell type with high accuracy on the basis of the image data of the stained cell nuclei for cells contained in a specimen such as cultured cells and tissue sections.
Absstract of: WO2026161273A1
Disclosed herein are antibodies, including anti-GPl antibodies that cross-react with more than one New World arenavirus and methods of using the anti-GPl antibodies.
Absstract of: WO2026160477A1
The present disclosure provides a novel technique for diagnosing STING-related diseases. Specifically, the present disclosure provides: a method comprising Step (A) for measuring a cyclic dinucleotide (CDN) present in a subject or obtaining information on the presence or level of the CDN, Step (B) for determining whether the CDN is derived from the subject and/or derived from a microorganism (parasite) expected to be contained in the subject, and Step (C) for diagnosing a STING-related disease or condition on the basis of the result of the determination; a therapeutic method related thereto; and the like.
Absstract of: US20260216227A1
The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.
Absstract of: US20260217758A1
0000 Disclosed herein are polypeptides comprising an extended recombinant polypeptide (XTEN) comprised of a plurality of overlapping sequence motifs and one or more barcode fragments releasable upon protease digestion and detectable from all other proteolytically releasable fragments. Certain embodiments of these polypeptides further comprise a biologically active polypeptide, wherein advantageous embodiments thereof comprise a releasable segment capable of proteolytic cleavage that cleaves the linkage between the XTEN polypeptide and the biologically active polypeptide. Methods of making and methods of using said polypeptides are also disclosed.
Absstract of: US20260217847A1
The present invention provides an anti-TfR1 single-domain antibody and a use thereof. The single-domain antibody includes a heavy chain variable region, wherein the heavy chain variable region includes a heavy chain CDR1 as shown in any one of SEQ ID NO: 53-SEQ ID NO: 60, a heavy chain CDR2 as shown in any one of SEQ ID NO: 61-SEQ ID NO: 72, and a heavy chain CDR3 as shown in any one of SEQ ID NO: 73-SEQ ID NO: 82.
Absstract of: US20260219284A1
Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of brain injuries, especially mild traumatic brain injury (mTBI) or concussion, are based upon detection of changes in levels of certain protein biomarkers in a subject undergoing testing, or upon detection of changes in levels of certain protein biomarkers in conjunction with neuroimaging analyses to detect changes in vascular or blood brain barrier (BBB) permeability in the brain, or to detect damage to fiber tracts in the brain, in which changes in biomarker levels correlate with detection of changes in BBB permeability or in brain fiber tract or white matter damage in a subject with brain injury such as mTBI or concussion.
Absstract of: WO2026158729A2
Provided in the present application are a pathogenic factor of neurodegenerative diseases and the use thereof. The pathogenic factor of neurodegenerative diseases is a PSAP-GPR37-IL-6 signaling axis. The present application specifies for the first time the action mechanism of the PSAP-GPR37-IL-6 signaling axis as a pathogenic factor of neurodegenerative diseases (especially Parkinson's disease), and reveals that oligodendrocytes regulate the molecular pathway of neuroinflammation and neurodegenerative changes via the signaling axis, thus filling the research gap in the prior art regarding the participation of oligodendrocytes in the pathogenesis of PD.
Absstract of: US20260219283A1
0000 Synucleinopathies are a group of neurodegenerative diseases including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). These diseases are characterized by the aggregation and deposition of α-synuclein (α-syn) in Lewy bodies (LBs) in PD and DLB or as glial cytoplasmic inclusions in MSA. In healthy brains, only ~4% of α-syn is phosphorylated at Ser129 (pS129-α-syn), whereas >90% pS129-α-syn may be found in LBs. Embodiments of the invention include a duplex assay for both total α-synuclein and pS129-α-synuclein, which allows measuring both analytes in the same sample, leading to substantial saving in sample volume. The assays can be widely used in methods for detecting pS129-α-syn in biomedical studies including when only a limited volume of sample is available and high sensitivity is required, offering new opportunities for diagnostic biomarkers, monitoring disease progression, and quantifying outcome measures in clinical trials.
Absstract of: US20260217667A1
Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are the methods for treating of diseases associated with an amyloid or amyloid like proteins.
Absstract of: US20260217804A1
Disclosed is an antibody or antigen-binding fragment thereof, which binds to AβpE3, i.e. to an N-terminally truncated and pyroglutamate-modified form of amyloid beta (Aβ), and therapeutic and diagnostic uses thereof.
Absstract of: US20260216327A1
0000 Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.
Absstract of: US20260219265A1
0000 Described is a method and device for detecting an analyte in a sample, comprising bringing a sample comprising a target analyte into contact with magnetisable particles, the particles being coated with binding molecules complementary to the target analyte, resulting in bound and unbound binder complexes, positioning the magnetisable particles, comprising both bound and unbound binder complexes, in proximity to a magnetic field sensor, changing the magnetic field sufficient to release at least a portion of the magnetisable particles, comprising both bound and unbound binder complexes, from their proximity to the magnetic field sensor, and measuring changes in a magnetic signal detected from the net movement, being either translational or rotational movement, of the magnetisable particles relative to the magnetic sensor.
Absstract of: WO2025006602A1
Provided herein are compositions and methods for detecting analytes in exosomes. In particular, the present invention relates to the capture and lysis of exosomes and detection of analytes in the exosomes using an immunoassay.
Absstract of: WO2017184873A2
Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.
Absstract of: EP4781999A1
0001 The present invention relates to Engrailed protein, a nucleic acid encoding Engrailed protein and compositions comprising the same for use in treating or preventing diseases associated with accumulation of TDP-43 in the cell, particularly in the cell cytoplasm. Also provided herein are in vitro methods of selecting a subject for such therapy by detecting cellular accumulation of TDP-43, particularly cellular cytoplasmic accumulation, in a biological sample of the subject. Also provided herein are in vitro methods of following a subject treated with such therapy by measuring cellular accumulation, particularly cellular cytoplasmic accumulation, of TDP-43 in a biological sample of the treated subject.
Absstract of: WO2025064229A1
The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.
Absstract of: CN122465005A
本申请涉及生物医药的技术领域，具体涉及一种靶向APOE蛋白HSPG结合区的单克隆抗体或其抗原结合片段、及其应用。该单克隆抗体或其抗原结合片段包括重链可变区和轻链可变区；重链可变区包括重链互补决定区CDRH1（SEQ ID NO:3）、CDRH2（SEQ ID NO:4）以及CDRH3（SEQ ID NO:5）；轻链可变区包括轻链互补决定区CDRL1（SEQ ID NO:6）、CDRL2（SEQ ID NO:7）以及CDRL3（SEQ ID NO:8）。本申请的单克隆抗体通过特异性阻断APOE与HSPG的病理性相互作用，为阿尔茨海默病等神经退行性疾病提供了一种全新的治疗策略。
Absstract of: CN122465007A
0001 本发明适用于生物医药技术领域，提供了一种琥珀酰化Tau单克隆抗体、制备方法和用途，所述抗体的重链可变区互补决定区CDR1、CDR2、CDR3的氨基酸序列分别如SEQ ID NO：1、2、3所示；所述抗体的轻链可变区互补决定区CDR1、CDR2、CDR3的氨基酸序列分别如SEQ ID NO：9、10、11所示。本发明提供一种单克隆抗体，该抗体能够高度特异性地结合su‑Tau，且不与未修饰的Tau或其他琥珀酰化修饰的相关肽段发生交叉反应，以该单克隆抗体为基础，采用独特的重复表位夹心法，可实现对琥珀酰化修饰Tau的高特异性、高灵敏度与高准确度检测。
Nº publicación: CN122466090A 28/07/2026
Applicant:
合肥凯祥弘康科技有限公司
Absstract of: CN122466090A
本发明公开了用于诊断认知障碍的标志物。本申请首次发现外泌体中C4b、C3d和DAF这三个标志物联合检测可显著提升认知障碍的诊断效能，能更全面、动态地反映认知障碍早期神经炎症驱动的病理过程，克服传统标志物的不足，为实现更高的早期诊断敏感性与特异性提供全新策略。
BOPI
Electronic site
